SCHEMBL6640482

SCHEMBL6640482

O=C(c1cccnc1)N1CCCC1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.66
MAPK1 P28482 1/20 0.66
ALDH1A1 P00352 2/20 0.65
HTT P42858 1/20 0.65
POLB P06746 1/20 0.64
MEN1 O00255 1/20 0.62
MAPT P10636 1/20 0.62
KMT2A Q03164 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
HPGD P15428 2/20 0.61
CHRNB2 P17787 1/20 0.59
CHRNB4 P30926 1/20 0.59
CHRNA3 P32297 1/20 0.59
CHRNA7 P36544 1/20 0.59
CHRNA4 P43681 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29457007 1.00 PKM (0.66) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL28324495 0.98 ALDH1A1 (0.67) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL29944134 0.98 ALDH1A1 (0.67) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL1569994 0.98 ALDH1A1 (0.67) PKMMAPK1ALDH1A1HTTPOLB
Hydrochloric Acid SCHEMBL27424417 0.97 ALDH1A1 (0.66) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL22702163 0.96 PKM (0.66) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL9763711 0.93 PKM (0.74) PKMMAPK1ALDH1A1POLBMEN1
Hydrochloric Acid SCHEMBL1596692 0.91 PKM (0.72) PKMMAPK1ALDH1A1POLBMEN1
SCHEMBL27857494 0.88 ALDH1A1 (0.64) PKMMAPK1ALDH1A1HTTPOLB
SCHEMBL27294663 0.86 PKM (0.62) PKMMAPK1ALDH1A1POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981892-B1 THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS UCB PHARMA SA (BE) 2014-03-12 EP claimed
CN-1700918-B N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase ANGELETTI P IST RICHERCHE BIO 2011-06-08 CN claimed
CN-1700918-A N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase ANGELETTI P IST RICHERCHE BIO (IT) 2005-11-23 CN claimed
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
US-11408085-B2 Galvanic nickel or nickel alloy electroplating bath for depositing a semi-bright nickel or semi-bright nickel alloy coating ATOTECH DEUTSCHLAND GMBH (DE) 2022-08-09 US disclosed
US-20220098747-A1 GALVANIC NICKEL OR NICKEL ALLOY ELECTROPLATING BATH FOR DEPOSITING A SEMI- BRIGHT NICKEL OR SEMI-BRIGHT NICKEL ALLOY COATING ATOTECH DEUTSCHLAND GMBH (DE) 2022-03-31 US disclosed
EP-3956498-A1 GALVANIC NICKEL OR NICKEL ALLOY ELECTROPLATING BATH FOR DEPOSITING A SEMI-BRIGHT NICKEL OR SEMI-BRIGHT NICKEL ALLOY COATING Atotech Deutschland GmbH & Co. KG (DE) 2022-02-23 EP disclosed
CN-113614290-A Electroplating nickel or nickel alloy electroplating bath for depositing semi-bright nickel or semi-bright nickel alloy coatings 德国艾托特克公司 2021-11-05 CN disclosed
CN-106998771-B Flavour composition and pet food comprising same 马斯公司 2021-06-22 CN disclosed
CN-107249349-B Methods for modulating taste receptors 马斯公司 2021-06-08 CN disclosed
EP-3319955-B1 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS GILEAD SCIENCES INC (US) 2020-11-25 EP disclosed
EP-0946508-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-10-06 EP disclosed
EP-0946528-A2 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS Du Pont Pharmaceuticals Company (US) 1999-10-06 EP disclosed
WO-1999032454-A1 NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-01 WO disclosed
WO-1999012903-A1 BENZIMIDAZOLINONES, BENZOXAZOLINONES, BENZOPIPERAZINONES, INDANONES, AND DERIVATIVES THEREOF AS INHIBITORS OF FACTOR XA DU PONT PHARMACEUTICALS COMPANY (US) 1999-03-18 WO disclosed
WO-1998057934-A1 (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-23 WO disclosed
WO-1998057937-A2 INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1998-12-23 WO disclosed
WO-1998057951-A1 NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-12-23 WO disclosed
WO-1998028269-A1 NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed
WO-1998028282-A2 OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT PKM 4405/4885MAPK1 4713/4885ALDH1A1 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.